Local ablative therapy for Minimal Residual Disease
Phase-Based Progress Estimates
Effectiveness
Safety
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, NJ
Minimal Residual Disease+8 More
Local ablative therapy - ProcedureEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared to systemic therapy.
Eligible Conditions
- Minimal Residual Disease
- Malignant Neoplasms
- Stage IV, NSCLC
- Non-small Cell Lung Cancer
- Nsclc
Treatment Effectiveness
Effectiveness Progress
Other trials for Minimal Residual Disease
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: 3 months +/- 2 weeks after enrollment
Month 3
Progression Free Survival/PFS
6 months
Measure the reduction in mean variant allele frequency/VAF by 6 months after Local Ablative Therapy/LAT
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Other trials for Minimal Residual Disease
Trial Design
3 Treatment Groups
Part II - standard of care
1 of 3
Part I
1 of 3
Part II - ablation to all sites of disease (experimental arm)
1 of 3
Active Control
Experimental Treatment
117 Total Participants · 3 Treatment Groups
Primary Treatment: Local ablative therapy · No Placebo Group · Phase 2
Part IExperimental Group · 2 Interventions: Local ablative therapy, Blood collection to assess for ctDNA · Intervention Types: Procedure, Other
Part II - ablation to all sites of disease (experimental arm)Experimental Group · 2 Interventions: Local ablative therapy, Blood collection to assess for ctDNA · Intervention Types: Procedure, Other
Part II - standard of care
Other
ActiveComparator Group · 1 Intervention: Blood collection to assess for ctDNA · Intervention Types: OtherTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months +/- 2 weeks after enrollment
Closest Location: Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, NJ
N/AFirst Recorded Clinical Trial
1 TrialsResearching Minimal Residual Disease
0 CompletedClinical Trials
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,806 Previous Clinical Trials
589,211 Total Patients Enrolled
1 Trials studying Minimal Residual Disease
Daniel Gomez, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
90 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have detectable ctDNA in blood.
You are a participant in the study.
You have received definitive treatment for Stage IV NSCLC
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments